“The pioneer of the MetaMouse® model”
AntiCancer Inc. is the foremost pre-clinical cancer contract research organization and has been in business since 1984.  AntiCancer offers orthotopic proteins and subcutaneous mouse models of all cancer types.  More than 100 models are available, all imageable with fluorescent proteins.
 
The AntiCancer team:
The AntiCancer team of twenty scientists is lead by Robert M. Hoffman, a world-leading cancer researcher.
· The AntiCancer team has unique skills in mouse models of cancer and their use in in vivo drug screening, evidenced by over 700 scientific publications and 175 world-wide patents
· AntiCancer has performed over 500 contract research projects for pharma, biotech and academia
· Dr. Hoffman was awarded the Sun Lee Prize in 2016 by the International Society for Experimental Microsurgery for the AntiCancer team’s development of it’s MetaMouse® orthotopic models
 
What we can do for you:
· Assist in model choice:  orthotopic or subcutaneous, xenograft or syngeneic
· Carry out your drug efficacy study with imageable endpoints of tumor growth, metastasis as well as survival
· Help you write and publish your paper
· Help you write your grant application and serve as a grant subcontractor
· We have helped many clients successfully apply for grants
· AntiCancer has received over 40 grants itself and has much experience in grant writing and applications
· AntiCancer has been designated as a “Success Story” by the National Cancer Institute
 
Cancer Xenograft Efficacy Models:
· All models are imageable
· Clinically-relevant orthotopic (literally “correct place”) tumor models (tumors implanted onto the organs of where the tumor originated)
· AntiCancer’s orthotopic models metastasize in the clinical pattern for each tumor type
· Subcutaneous xenograft models
· A choice of more than 100 cancer cell lines including the NCI-60 cancer cell line panel
· The cell lines have been characterized in-house for tumorigenicity and metastasis
· Patient-derived orthotopic xenograft (PDOX) models from multiple tumor types available
· PDOX models are orthotopic and metastasize, in contrast to subcutaneous PDX models
· Client-produced cell lines for your in vivo studies
· Models of every cancer type for your in vivo studies
· Metastatic models - all orthotopic models metastasize
· Syngeneic models, including B16 melanoma, Lewis lung carcinoma (LLC), 4T1 breast cancer, CT26 colon cancer and PAN02 pancreatic cancer in immunocompetent mice
 
Endpoints:
AntiCancer can help you obtain high-quality, meaningful and publishable data from every study.  Endpoints in oncology studies include:
 
· Tumor size reduction and regression - data available in real-time with imaging with resolution of a single cancer cell in vivo.
· Tumor growth delay or regression
· Decrease or elimination of metastasis - data are available with real-time imaging
· Drug effects on host and tumor
· Increase in overall survival and disease-free survival
· Changes in biomarkers